ATE353666T1 - Verwendung von aktiviertem gerinnungsfaktor vii zur behandlung von durch thrombolytische therapie-induzierten wichtigen blutungen - Google Patents

Verwendung von aktiviertem gerinnungsfaktor vii zur behandlung von durch thrombolytische therapie-induzierten wichtigen blutungen

Info

Publication number: ATE353666T1
Authority: AT; Austria
Prior art keywords: factor vii; treatment; clotting factor; thrombolytic therapy; activated clotting
Prior art date: 2000-12-21

Application number

AT01995705T

Other languages

English (en)

Inventor

Cord Skamira

Jean Marie Stassen

Gerhard Heusel

Wolfgang Wienen

Original Assignee

Boehringer Ingelheim Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-21

Filing date

2001-12-20

Publication date

2007-03-15

2001-12-20 Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma

2007-03-15 Application granted granted Critical

2007-03-15 Publication of ATE353666T1 publication Critical patent/ATE353666T1/de

Links

230000000740 bleeding effect Effects 0.000 title abstract 3
239000003146 anticoagulant agent Substances 0.000 title abstract 2
230000002537 thrombolytic effect Effects 0.000 title abstract 2
102000015081 Blood Coagulation Factors Human genes 0.000 title 1
108010039209 Blood Coagulation Factors Proteins 0.000 title 1
239000003114 blood coagulation factor Substances 0.000 title 1
229940012413 factor vii Drugs 0.000 title 1
208000032843 Hemorrhage Diseases 0.000 abstract 2
208000034158 bleeding Diseases 0.000 abstract 2
231100000319 bleeding Toxicity 0.000 abstract 2
102100023804 Coagulation factor VII Human genes 0.000 abstract 1
108010023321 Factor VII Proteins 0.000 abstract 1
206010018985 Haemorrhage intracranial Diseases 0.000 abstract 1
229940105772 coagulation factor vii Drugs 0.000 abstract 1
239000003527 fibrinolytic agent Substances 0.000 abstract 1
230000003480 fibrinolytic effect Effects 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
General Chemical & Material Sciences (AREA)
Hematology (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Enzymes And Modification Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)

AT01995705T 2000-12-21 2001-12-20 Verwendung von aktiviertem gerinnungsfaktor vii zur behandlung von durch thrombolytische therapie-induzierten wichtigen blutungen ATE353666T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP00128252A EP1216709A1 (de)	2000-12-21	2000-12-21	Verwendung von aktiviertem Gerinnungsfaktor VII zur Behandlung von durch thrombolytische Therapie-induzierten wichtigen Blutungen

Publications (1)

Publication Number	Publication Date
ATE353666T1 true ATE353666T1 (de)	2007-03-15

Family

ID=8170769

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01995705T ATE353666T1 (de)	2000-12-21	2001-12-20	Verwendung von aktiviertem gerinnungsfaktor vii zur behandlung von durch thrombolytische therapie-induzierten wichtigen blutungen

Country Status (25)

Country	Link
US (2)	US20040087502A1 (de)
EP (2)	EP1216709A1 (de)
JP (1)	JP2004516273A (de)
KR (1)	KR20030063454A (de)
CN (1)	CN1482919A (de)
AT (1)	ATE353666T1 (de)
AU (2)	AU2638602A (de)
BR (1)	BR0116151A (de)
CA (1)	CA2431986A1 (de)
CY (1)	CY1106363T1 (de)
CZ (1)	CZ300670B6 (de)
DE (1)	DE60126650T2 (de)
DK (1)	DK1343523T3 (de)
EC (1)	ECSP034647A (de)
ES (1)	ES2280429T3 (de)
HU (1)	HUP0302574A3 (de)
IL (1)	IL155886A0 (de)
MX (1)	MXPA03005641A (de)
NZ (1)	NZ549850A (de)
PL (1)	PL205878B1 (de)
PT (1)	PT1343523E (de)
RU (1)	RU2286796C2 (de)
SI (1)	SI1343523T1 (de)
WO (1)	WO2002049665A2 (de)
ZA (1)	ZA200304140B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005123118A1 (en) *	2004-06-21	2005-12-29	Novo Nordisk Health Care Ag	Use of factor viia or factor viia equivalents for preventing or attenuating haemorrhage growth, and/or oedema generation following intracerebral haemorrhage (ich)
RU2396086C2 (ru) *	2004-09-10	2010-08-10	Фармаоригин Апс	Способы лечения трахеального, бронхиального или альвеолярного кровотечения или кровохарканья
US20090156481A1 (en) *	2005-07-15	2009-06-18	Novo Nordisk Healthcare A/G	Use of Factor VIIa or Factor VIIa Equivalents for Preventing or Attenuating Haemorrhage Growth, and/or Oedema Generation Following Intracerebral Haemorrhage (ICH) in Patients Treated with Antiplatelet Therapy
JP2011509978A (ja)	2008-01-18	2011-03-31	ノボノルディスクヘルスケアアーゲー	選択されたＩＣＨ患者亜集団における脳内出血（ＩＣＨ）後の出血拡大、及び／又は浮腫生成の予防又は減弱のための、第ＶＩＩａ因子又は第ＶＩＩａ因子等価物の使用
RU2552339C1 (ru) *	2014-02-19	2015-06-10	Общество с ограниченной ответственностью фирма "Технология-Стандарт"	Способ профилактики кровотечений, вызванных применением стрептокиназы, в эксперименте

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4382082A (en) *	1980-12-18	1983-05-03	Uop Inc.	Recovery of cobalt values by absorption from ammoniacal solution
ZA862768B (en) *	1985-04-17	1986-12-30	Zymogenetics Inc	Expression of factor vii and ix activities in mammalian cells
US5374617A (en) *	1992-05-13	1994-12-20	Oklahoma Medical Research Foundation	Treatment of bleeding with modified tissue factor in combination with FVIIa
US5846517A (en) *	1996-09-11	1998-12-08	Imarx Pharmaceutical Corp.	Methods for diagnostic imaging using a renal contrast agent and a vasodilator
AU7907398A (en) *	1997-06-23	1999-01-04	Novo Nordisk A/S	Use of fviia for the treatment of bleedings in patients with a normal blood clotting cascade and normal platelet function

2000
- 2000-12-21 EP EP00128252A patent/EP1216709A1/de not_active Withdrawn
2001
- 2001-12-20 ES ES01995705T patent/ES2280429T3/es not_active Expired - Lifetime
- 2001-12-20 DK DK01995705T patent/DK1343523T3/da active
- 2001-12-20 MX MXPA03005641A patent/MXPA03005641A/es active IP Right Grant
- 2001-12-20 PT PT01995705T patent/PT1343523E/pt unknown
- 2001-12-20 DE DE60126650T patent/DE60126650T2/de not_active Expired - Lifetime
- 2001-12-20 EP EP01995705A patent/EP1343523B1/de not_active Expired - Lifetime
- 2001-12-20 PL PL361855A patent/PL205878B1/pl not_active IP Right Cessation
- 2001-12-20 KR KR10-2003-7008408A patent/KR20030063454A/ko not_active Ceased
- 2001-12-20 BR BR0116151-2A patent/BR0116151A/pt not_active Application Discontinuation
- 2001-12-20 JP JP2002551003A patent/JP2004516273A/ja active Pending
- 2001-12-20 SI SI200130694T patent/SI1343523T1/sl unknown
- 2001-12-20 IL IL15588601A patent/IL155886A0/xx not_active IP Right Cessation
- 2001-12-20 AT AT01995705T patent/ATE353666T1/de not_active IP Right Cessation
- 2001-12-20 NZ NZ549850A patent/NZ549850A/en unknown
- 2001-12-20 CZ CZ20031743A patent/CZ300670B6/cs not_active IP Right Cessation
- 2001-12-20 HU HU0302574A patent/HUP0302574A3/hu unknown
- 2001-12-20 RU RU2003122362/15A patent/RU2286796C2/ru not_active IP Right Cessation
- 2001-12-20 WO PCT/EP2001/015132 patent/WO2002049665A2/en not_active Ceased
- 2001-12-20 AU AU2638602A patent/AU2638602A/xx active Pending
- 2001-12-20 CA CA002431986A patent/CA2431986A1/en not_active Abandoned
- 2001-12-20 US US10/451,615 patent/US20040087502A1/en not_active Abandoned
- 2001-12-20 CN CNA018211119A patent/CN1482919A/zh active Pending
- 2001-12-20 AU AU2002226386A patent/AU2002226386B2/en not_active Ceased
2003
- 2003-05-28 ZA ZA200304140A patent/ZA200304140B/en unknown
- 2003-06-11 EC EC2003004647A patent/ECSP034647A/es unknown
2007
- 2007-03-08 CY CY20071100327T patent/CY1106363T1/el unknown
2008
- 2008-07-10 US US12/170,916 patent/US20080286259A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CY1106363T1 (el)	2011-10-12
IL155886A0 (en)	2003-12-23
ECSP034647A (es)	2003-07-25
ZA200304140B (en)	2004-04-22
NZ549850A (en)	2008-04-30
HUP0302574A2 (hu)	2003-10-28
US20080286259A1 (en)	2008-11-20
RU2003122362A (ru)	2005-02-10
HUP0302574A3 (en)	2010-01-28
PL205878B1 (pl)	2010-06-30
RU2286796C2 (ru)	2006-11-10
US20040087502A1 (en)	2004-05-06
CN1482919A (zh)	2004-03-17
CZ300670B6 (cs)	2009-07-15
SI1343523T1 (sl)	2007-04-30
AU2638602A (en)	2002-07-01
MXPA03005641A (es)	2004-12-03
BR0116151A (pt)	2003-10-21
PT1343523E (pt)	2007-03-30
ES2280429T3 (es)	2007-09-16
AU2002226386B2 (en)	2005-12-22
WO2002049665A3 (en)	2002-09-26
EP1216709A1 (de)	2002-06-26
DE60126650T2 (de)	2007-10-31
KR20030063454A (ko)	2003-07-28
PL361855A1 (en)	2004-10-04
CA2431986A1 (en)	2002-06-27
EP1343523B1 (de)	2007-02-14
JP2004516273A (ja)	2004-06-03
DE60126650D1 (de)	2007-03-29
DK1343523T3 (da)	2007-04-10
CZ20031743A3 (cs)	2003-11-12
EP1343523A2 (de)	2003-09-17
WO2002049665A2 (en)	2002-06-27

Legal Events

Date

Code

Title

Description

2007-08-15

UEP

Publication of translation of european patent specification

Ref document number: 1343523

Country of ref document: EP

2011-09-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE552842T1 (de)	2012-04-15	Verwendung von plasminogen zur wundheilung
PT1336605E (pt)	2006-06-30	Derivados de fenol substituidos ou seus sais como inibidores do factor x de coagulacao
DE602004018338D1 (de)	2009-01-22	Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund
DE69022150D1 (de)	1995-10-12	Neue Peptidasen und Isomerasen-Inhibitoren.
PT816376E (pt)	2003-02-28	Inibidores de trombina como agentes anticoagulantes
ATE444086T1 (de)	2009-10-15	Therapeutische zusammensetzungen und verfahren zur behandlung von periodontitis mit entzündunshemmenden mitteln
NO20025405D0 (no)	2002-11-11	Modulatorer for TNF-alfa-signalisering
ATE353666T1 (de)	2007-03-15	Verwendung von aktiviertem gerinnungsfaktor vii zur behandlung von durch thrombolytische therapie-induzierten wichtigen blutungen
ATE359808T1 (de)	2007-05-15	Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
ATE402694T1 (de)	2008-08-15	Verwendung von 1-phenyl-3-dimethylamino-propan- verbindungen zur therapie der harninkontinenz
PT1268463E (pt)	2005-05-31	4-pironas substituidas com arilo e heteroarilo policiclicos uteis para a inibicao selectiva da cascata de coagulacao
ATE430578T1 (de)	2009-05-15	Faktor viii oder von willebrand faktor zur behandlung von thrombopathie assoziierenden hämorrhagischen erkrankungen
DE60128084D1 (de)	2007-06-06	Verwendung von inaktives cln2 proenzym zur behandlung von lincl
ATE315387T1 (de)	2006-02-15	Verwendung von substituierten 6- dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz
ATE314066T1 (de)	2006-01-15	Verwendung von buprenorphin zur therapie der harninkontinenz
ATE337790T1 (de)	2006-09-15	Verwendung von cortisol-sequestriermitteln zur behandlung von hypercortisolaemie-verwandten erkrankungen
ATE311901T1 (de)	2005-12-15	Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten
ATE415165T1 (de)	2008-12-15	Kombinierte tumortherapie auf der basis von distamycin-acryloyl derivate und antimetabolische mitteln
ATE288263T1 (de)	2005-02-15	Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis)
ATE360437T1 (de)	2007-05-15	Verwendung des blutgerinnungsfaktors xiii für die behandlung der hämophilie a
ATE336261T1 (de)	2006-09-15	Blutgerinnungsfaktor xiii zur behandlung von plättchenfunktionsstörungen
FR2816633B1 (fr)	2003-02-07	Methode de criblage d'agents susceptibles de traiter l'obesite